Evidence map›Paper›PMID 33752511›Full record

ArticleThe Journal of international medical research2021

High serum levels of CA 19-9 and CYFRA21-1 caused by renal pelvis urothelial carcinoma: a report of two cases.

Guolin Yin, Miaomiao Zhang, Bing Zhao, Zaixing Yang

Abstract readCase Reports
In one paragraph

Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guolin YinDepartment of Urology, Taizhou First People's Hospital, Zhejiang, China.
Miaomiao ZhangDepartment of Laboratory Medicine, Taizhou First People's Hospital, Zhejiang, China.
Bing ZhaoDepartment of Laboratory Medicine, Taizhou First People's Hospital, Zhejiang, China.
Zaixing YangDepartment of Laboratory Medicine, Taizhou First People's Hospital, Zhejiang, China.ORCID https://orcid.org/0000-0002-7545-642X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbohydrate antigen 19-9 (CA19-9) and cytokeratin 19 fragment (CYFRA21-1) are widely used as tumor markers in clinical practice and are increased in many neoplasms. However, although increased serum CA19-9 levels have been found in some Japanese patients with renal urothelial carcinoma (UC), they have not been detected in patients from other countries or regions, and increased serum CYFRA21-1 levels haves not been reported in patients with renal UC. We analyzed serum CA19-9 and CYFRA21-1 levels in two patients with renal UC and monitored the changes in levels during postoperative follow-up. Both cases with renal pelvis UC had high levels of serum CA19-9 and CYFRA21-1, which decreased to within normal ranges after successful surgery, suggesting a causal relationship between renal UC and increased serum CA19-9 and CYFRA21-1. Because serum levels of CA19-9 and CYFRA21-1 are increased in many neoplastic diseases, they may not be reliable tumor markers for the screening and diagnosis of renal UC. However, they may be useful noninvasive indicators for assessing treatment effects in patients with renal pelvis UC with elevated pretreatment serum CA19-9 or CYFRA21-1.

Indexed as

CA-19-9 AntigenLung NeoplasmsAntigens, NeoplasmBiomarkers, TumorHumansKeratin-19Kidney Pelvisantigen CYFRA21.1Antigens, NeoplasmBiomarkers, TumorCA-19-9 AntigenKeratin-19Carbohydrate antigen 19-9cytokeratin 19 fragmentfollow-uprenal urothelial carcinomatreatment effecttumor marker

Identifiers

PMID33752511
PMCPMC7995450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.